CD38 and NMN: Why Apigenin Belongs in Your NAD+ Formula

What Is CD38?

CD38 is an enzyme found on cell membranes and inside cells throughout the body, with high activity in the liver, brain, heart, spleen, and kidney. Its defining property in the context of aging is simple: CD38 consumes NAD+. It is classified as an NADase, meaning its job is to break the NAD+ molecule apart.

Most longevity conversations focus entirely on making more NAD+. That is only half of the system. NAD+ levels at any moment reflect a balance between synthesis and degradation. You can pour more raw material into the synthesis side, but if the degradation side is running faster than it used to, the net gain is smaller than expected.

CD38 is the single largest consumer of NAD+ in mammalian tissue. Researchers at Mayo Clinic established it as the primary NADase in mammals, which makes it the most consequential enzyme on the degradation side of the ledger.

Why CD38 Increases With Age

CD38 activity does not stay flat across a lifetime. Protein levels and enzymatic activity of CD38 rise measurably in multiple tissues as animals age, and this increase tracks directly with the fall in tissue NAD+.

This finding reframed the field. For years the assumption was that NAD+ falls with age because the body makes less of it. The Mayo Clinic work pointed somewhere else: a substantial share of the decline is driven by an enzyme that destroys NAD+ becoming more abundant and more active over time.

The likely trigger is inflammation. CD38 expression is induced by inflammatory signals, and chronic low-grade inflammation is a well-documented feature of aging. The result is a self-reinforcing loop where inflammation raises CD38, CD38 lowers NAD+, and lower NAD+ impairs the Sirtuin-driven repair processes that would otherwise help regulate inflammation.

CD38 Degrades NMN Before It Becomes NAD+

This is the finding that matters most for anyone taking an NMN supplement. In the same 2016 Cell Metabolism paper, the Mayo Clinic team identified CD38 as the main enzyme involved in the degradation of nicotinamide mononucleotide in living tissue.

NMN is not NAD+. It is a precursor, converted to NAD+ inside your cells through the NMNAT pathway. That conversion takes time, and during that window the NMN molecule is exposed. If CD38 activity is elevated, a portion of the NMN you take is broken down before it ever reaches the enzyme that would have converted it.

The authors of the study made this point explicitly, noting that CD38 has a key role in the modulation of NAD+ replacement therapy. In plain terms: how well NMN supplementation works depends in part on how active your CD38 is.

What Is Apigenin and How Does It Inhibit CD38?

Apigenin is a flavonoid found in chamomile, parsley, celery, and several other plants. It came to the attention of longevity researchers for one specific reason: it inhibits CD38.

The same study went further than cell culture. When apigenin was administered to obese mice, NAD+ levels increased, global protein acetylation decreased (a downstream marker of Sirtuin activity), and several measures of glucose and lipid handling improved. The authors concluded that CD38 is a viable pharmacological target for influencing NAD+ dependent pathways.

A separate 2020 study extended the finding to a different tissue and disease model.

Apigenin is not the only flavonoid with this property. Work published in 2011 screened a range of flavonoids and found several that inhibit human CD38 at low micromolar concentrations, confirming that this is a genuine chemical class effect rather than a single anomalous result.

The Second Role: Inflammation

Apigenin has a well-documented anti-inflammatory profile, and this matters more than it first appears. Recall that CD38 expression is induced by inflammatory signalling. A compound that both inhibits the enzyme and reduces the signal that drives its production is acting at two points on the same pathway rather than one.

Being precise about the limits here: the CD38 inhibition and the anti-inflammatory activity are each independently documented. Whether the second meaningfully reduces CD38 induction in humans over time has not been directly tested. The two roles are complementary on paper. That is a sound reason to include the compound, and it is not the same as a demonstrated combined effect.

Why NMN and Apigenin Work Better Together

Add the fuel, then stop the drain. That is the whole idea, and it is the reason this pairing exists.

The logic is structural rather than additive. NMN and apigenin do not do the same thing more strongly. They act on opposite ends of the same system. NMN supplies the raw material for NAD+ synthesis. Apigenin reduces the activity of the enzyme that consumes NAD+ and degrades NMN. One increases input. The other reduces loss. A formula that includes only the precursor is optimising half of a two-sided balance.

This is the reasoning behind the dual NAD+ system architecture in PRECISION LONGEVITY. The formula contains eight compounds, and each is mapped to a specific mechanism rather than included for label appeal.

Those levers group into three layers. Boost covers NAD+ supply and mitochondrial output, replenishing the NAD+ every cell runs on and fuelling the mitochondria that turn it into usable energy. Protect covers inflammatory balance, oxidative defense, and cellular cleanup, calming the low-grade inflammation that quietly ages tissue and neutralising the free radicals that wear cells down. Renew covers senescent cell clearance and DNA protection, addressing the cells that stop working but refuse to die and supporting the repair processes that handle daily DNA damage.

Several compounds appear under more than one lever. That is deliberate rather than padding. Astaxanthin contributes to three, apigenin to two. Every active in the formula has a named job, and none is present to make the label longer.

What the Evidence Does and Does Not Show

Accuracy matters more than enthusiasm here, so it is worth being precise about the state of the research.

What is well established: CD38 is the primary NADase in mammalian tissue. CD38 expression and activity increase with age. CD38 is required for age-related NAD+ decline in animal models. CD38 is the main enzyme degrading NMN in vivo. Apigenin inhibits CD38 and raises intracellular NAD+ in cell and animal studies.

What is not yet established: the apigenin CD38 evidence comes from cell culture and rodent models. There are no large human trials measuring the effect of oral apigenin on human NAD+ levels, and none testing an NMN plus apigenin combination against NMN alone in people. The mechanism is well characterised. The human outcome data is not there yet.

What to Look For in an NMN Formula

If you are evaluating NMN products, the CD38 question is a useful filter. Most formulas on the market address only NAD+ synthesis. A smaller number address degradation as well.

Check the ingredient rationale. Every compound in a formula should have a stated mechanism. Long ingredient lists with no explanation of why each is present usually indicate marketing rather than formulation.

Check the doses. Compounds included below any studied threshold are label decoration. Doses should be disclosed per serving rather than hidden inside a proprietary blend.

Check whether NMN and NR are being conflated. Nicotinamide mononucleotide and nicotinamide riboside are distinct molecules that enter the NAD+ pathway at different points. Research on one does not automatically transfer to the other, and formulas that blur this distinction are not reading the literature carefully.

Check who formulated it. A named scientist with relevant training is accountable for the decisions in a formula in a way that an anonymous brand is not.